Add-on voclosporin improved complete renal response across all lupus nephritis biopsy classes, with the greatest benefit observed in pure class 3.
A comprehensive meta-analysis quantified the risks of several cardiovascular diseases in patients with systemic lupus erythematosus (SLE).
CD62L, a basophil activation marker, may be a noninvasive prognostic biomarker that can be used to treat patients with severe lupus nephritis.
Patients with new-onset lupus nephritis achieve significantly higher rates of complete response at 1, 2, and 3 years if they receive a higher initial dose of prednisone for remission induction, a study found.
This the first study to evaluate the risk for venous thromboembolism by lupus nephritis class, according to investigators.
Among patients with systemic lupus erythematosus, mortality is increased for minorities, especially Asian, Hispanic/Latina women
Study findings support the utility of the 2019 EULAR/ACR classification in everyday nephrology clinical practice.
Over 20 years, 8.4% of patients with lupus developed end-stage kidney disease, a study found.
Despite the disappointing results of randomized controlled trials such as LUNAR, targeting B cells remains an attractive option in patients with lupus nephritis, according to investigators.
In a study, approximately one-third of patients with lupus membranous nephritis tested positive for the proteins exostosin 1/exostosin 2.